Oculis (NASDAQ:OCS) Shares Gap Up – Still a Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) gapped up before the market opened on Friday . The stock had previously closed at $18.70, but opened at $20.35. Oculis shares last traded at $20.41, with a volume of 64,061 shares.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on OCS. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Monday, January 6th. Chardan Capital restated a “buy” rating and issued a $28.00 price objective on shares of Oculis in a research report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $28.80.

Oculis Price Performance

The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $856.66 million, a price-to-earnings ratio of -10.96 and a beta of -0.33. The company has a 50 day moving average price of $16.48 and a 200 day moving average price of $13.99.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.